Albireo Energy Announces CEO Succession as Company Enters Next Stage of Accelerated Expansion
Albireo Energy Earns Great Place To Work Certification™ for Eighth Consecutive Year
Albireo Energy Names Mergers and Acquisitions Executive
Albireo Energy Strengthens Presence in Arizona with Local Leadership and Proven Expertise
Albireo Energy Launches Private Cloud Services to Enhance Building System Data Security and Performance
Albireo Launches Critical Alarm Management Service for Mission Critical Buildings that Require Uptime and Reliability
Albireo Energy Sees Buildings in a Different Way as it Unveils New Brand Identity
Is Albireo Pharma (ALBO) Stock Outpacing Its Medical Peers This Year?
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations
Albireo Pharma: Elucidating The Ipsen Buyout (Rating Upgrade)
2 Tiny Nasdaq Stocks Making Major Merger Moves Monday
Albireo Pharma, Inc. (ALBO) Q3 2022 Earnings Call Transcript
Albireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue Estimates
Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022
Albireo to Report Q3 2022 Financial Results on November 8, 2022
Albireo: Strong Phase 3 Data Foretells More Upside
Albireo (ALBO) Up on Results From Alagille Syndrome Study
Albireo's stock is up 10% on plans to seek FDA approval for drug for rare disorder
Albireo Pharma: Assessing The Sagard Deal
Albireo Pharma (ALBO) Stock Jumps 11%: Will It Continue to Soar?
Albireo to Participate in Upcoming Investor Conferences
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q2 2022 Results - Earnings Call Transcript
Albireo Pharma (ALBO) Reports Q2 Loss, Misses Revenue Estimates
Is Albireo Pharma (ALBO) Outperforming Other Medical Stocks This Year?
Has Albireo Pharma (ALBO) Outpaced Other Medical Stocks This Year?
Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Albireo to Present at the William Blair Biotech Focus Conference 2022
Albireo to Present New Data at the 54th Annual Meeting of ESPGHAN
Albireo to Participate at Upcoming Investor Conferences
Albireo to Participate in the H.C. Wainwright Global Investment Conference 2022
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q1 2022 Results - Earnings Call Transcript
Albireo Pharma (ALBO) Reports Q1 Loss, Lags Revenue Estimates
Albireo to Report Q1 2022 Financial Results on May 16
Albireo: A Speculative Play With Upside
Is a Surprise Coming for Albireo Pharma (ALBO) This Earnings Season?
Adult Liver Diseases: The R&D Engine Drives Albireo's Long-Term Prospects.
Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Wall Street Analysts Predict an 184% Upside in Albireo Pharma (ALBO): Here's What You Should Know
Albireo Pharma Stock (ALBO): Why The Price Increased
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022
Albireo: Reasons For A Successful Transformation Into A Commercial Company
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q3 2021 Results - Earnings Call Transcript
Albireo Pharma (ALBO) Reports Q3 Loss, Lags Revenue Estimates
Albireo to Report Third Quarter 2021 Financial Results on November 4
Albireo to Showcase New Data at AASLD The Liver Meeting® 2021
Albireo Announces Exclusive Licensing Agreement with Jadeite Medicines for Bylvay™ (odevixibat) in Japan
Albireo Recognizes PFIC Awareness Day 2021
Albireo Announces Bylvay® (odevixibat) Now Available in Germany
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Albireo Receives UK MHRA Approval of Bylvay® (odevixibat)